What's new?

Added 10 hours ago Drug news

FDA expands approval of PD-L1 IHC 22C3 pharmDx assay in NSCLC

Agilent Technologies announced that the FDA has updated its approval of the company’s PD-L1 IHC 22C3 pharmDx assay. The assay...

Added 10 hours ago Drug news

Motif Bio plc announced new iclaprim data are presented at the 28th European Congress of Clinical Microbiology and Infectious Diseases meeting.

Motif Bio plc announced that new iclaprim data are being presented at the 28th European Congress of Clinical Microbiology and...

Added 1 day ago Drug news

Stryker launches in the US its defibrillation solution, the LIFEPAK CR2 defibrillator.

Stryker has launched the company’s newest defibrillation solution, the LIFEPAK CR2 defibrillator with LIFELINKcentral AED program manager, in the United...

Added 1 day ago Drug news

Phase III STR1VE trial in spinal muscular atrophy (SMA) Type 1 releases interim data

AveXis, a Novartis company, announced that interim data from its Phase III STR1VE trial of Zolgensma (onasemnogene abeparvovec-xioi; AVXS-101) in...

Added 10 hours ago Drug news

Pfizer has begun enrollment in three Phase III trials evaluating 20-Valent pneumococcal conjugate vaccine in adults.

Pfizer Inc. announced at the end of 2018, the initiation of a Phase III program for its 20-Valent pneumococcal conjugate...

Added 1 day ago Drug news

Mesoblast Ltd makes rolling submission to FDA for remestemcel-L in children with steroid-refractory acute graft versus host disease.

Mesoblast Limited announced that the FDA has agreed that Mesoblast can submit on a rolling basis a Biologics License Application...

Added 2 days ago Drug news

Brolucizumab licence application to treat wet age-related macular degeneration

Novartis announced that the FDA accepted the company's Biologics License Application (BLA) for brolucizumab (RTH 258) for the treatment of...